申联生物医药（上海）股份有限公司2025年度业绩快报公告

Financial Performance Summary - In 2025, the company achieved operating revenue of 288.27 million RMB, a decrease of 4.99% compared to the previous year [3] - The net profit attributable to the parent company was a loss of 19.09 million RMB, which represents a reduction in losses by 57.33% year-on-year [3] - Total assets at the end of the reporting period were 1.54 billion RMB, a decrease of 0.71% from the beginning of the year [3] - The equity attributable to the parent company was 1.39 billion RMB, down 1.47% from the beginning of the year [3] Operational Factors - The company continued to expand into new areas of biopharmaceutical technology, enhancing product market competitiveness and optimizing marketing strategies [4] - Despite increased sales volume due to entry into large aquaculture supply chains, revenue and gross margin slightly declined due to competitive pricing pressures in the animal health industry [4] - Delays in customer payments led to an increase in accounts receivable and higher credit impairment losses [4] - The company adjusted its operational strategy, focusing on customer needs and achieving progress in the development of multi-valent vaccines [4] Investment and Future Plans - The company invested in a stake in an innovative drug company, Yangzhou Shizhi Source Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [5] - The company plans to gain controlling interest in Shizhi Source through its wholly-owned subsidiary, Shanghai Bentiancheng Biotechnology Co., Ltd., integrating it into the consolidated financial statements [5] - Future plans include leveraging biotechnological advantages to accelerate the development and launch of innovative drugs, including treatments for HIV and allergy monoclonal antibodies [6] Credit Impairment Provision - The company plans to recognize a credit impairment provision of 12.76 million RMB for the year 2025 [11] - This provision is based on expected credit losses from accounts receivable, notes receivable, and other receivables [11] - The impact of this provision on the company's total profit for 2025 is estimated to be 12.76 million RMB, excluding tax effects [12]